Loss-Making Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Expected To Breakeven

Aimmune Therapeutics, Inc.'s (NASDAQ:AIMT): Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company…